Helix BioPharma Announces $11.4 Million Private Placement

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, Ontario, Sept. 30 /CNW/ -- Helix BioPharma Corp. (TSX, FSE:\n"HBP") today announced that it has received subscriptions for the purchase, by\nway of private placement, of a total of 6,800,000 units at $1.68 per unit, for\ngross proceeds totaling CDN$11,424,000. The Company anticipates closing the\nprivate placement within the next ten days.\n\n\n\n\n\nEach unit consists of one common share and one-half of one common share\npurchase warrant, with each whole common share purchase warrant entitling the\nholder to purchase one common share at a price of $2.36 for up to three years\nafter the closing date of the private placement.\n\n\n\n\n\n"This is an exciting time for Helix as we open clinical trial sites in\nGermany for our trial of Topical Interferon Alpha-2b for the treatment of\nano-genital warts, prepare for additional clinical trials for this treatment\nand continue to progress towards clinical testing with L-DOS47," said John\nDocherty, president of Helix BioPharma. "We plan to use the proceeds from the\nplacement for working capital, primarily to support these research and\ndevelopment initiatives."\n\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha- 2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP".\n\n\n\n\n\nFor further information contact:\n\n\nInvestor & Media Relations\nIan Stone\nRusso Partners LLC\nTel: (619) 814-3510\nFax: (619) 955-5318\nEmail: [email protected]\n\n\nDavid Schull\nRusso Partners LLC\nTel: (212) 845-4271\nEmail: [email protected]\nwww.russopartnersllc.com\n\n\n\n\nThe Toronto and Frankfurt Stock Exchanges have not reviewed and do not\naccept responsibility for the adequacy or accuracy of the content of this News\nRelease. This News Release contains forward-looking statements and information\nregarding a proposed private placement and the Company's activities, which\nstatements and information can be identified by the words "anticipates,\n"next", "...

More updates from Helix Biopharma Corp.